IRAK
IRAK(白细胞介素受体相关激酶)
Interleukin receptor-associated kinase (IRAK) is a family of serine/threonine-protein kinase that plays a vital role in innate immune immunity. It is involved in the TLR and IL-1R signaling pathways which associated with the autoimmune and inflammatory diseases.
IRAK 相关产品(32)
- GC11103IRAK inhibitor 3CAS: 1012343-93-9纯度: >98.00%
IRAK inhibitor 3 是一种从专利 WO2008030579 A2 中提取的白细胞介素-1 (IL-I) 受体相关激酶 (IRAK) 激酶调节剂。
- GC19287PF06650833CAS: 1817626-54-2纯度: >99.50%
PF06650833 (PF-06650833) 是一种有效的、选择性的和口服活性的白细胞介素 1 受体相关激酶 4 (IRAK4) 抑制剂,在细胞和 PBMC 试验中的 IC50 分别为 0.2 和 2.4 nM。
- GC20007Ginsenoside CKCAS: 39262-14-1纯度: >98.00%
Ginsenoside CK,一种由主要人参皂苷化合物转化而来的次级人参皂苷,比其母体人参皂苷具有更高的生物利用度和溶解性,具有极其重要的意义。
- GC31688IRAK4-IN-1CAS: 1820787-94-7纯度: >99.00%
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with IC50 of 7 nM.
- GC36328IRAK inhibitor 4 trans纯度: >99.00%
IRAK inhibitor 4 (trans)是IRAK inhibitor 4的trans形式,IRAK inhibitor 4是IRAK4的有效抑制剂。
- GC38799IRAK4-IN-4CAS: 1850276-58-2纯度: >99.50%
IRAK4-IN-4 (compound 15) is an inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) and cyclic GMP-AMP synthase (cGAS) with IC50 of 2.8 nM and 2.1 nM, respectively.
- GC61944IRAK4-IN-6CAS: 2454244-02-9纯度: >99.50%
IRAK4-IN-6 是一种口服高效、选择性 IRAK 抑制剂,IC50 为 4 nM,靶向 MyD88 L265P 突变型弥漫性大 B 细胞淋巴瘤。
- GC62197PROTAC IRAK4 degrader-1CAS: 2360533-90-8纯度: >99.50%
PROTAC IRAK4 degrader-1 是一种 PROTAC IRAK4 降解剂,详细信息请参考专利文献 US20190192668A1 中的化合物 I-210。PROTAC IRAK4 degrader-1 浓度为 0.01,0.1 和 1 μM 时作用于 OCI-LY-10 细胞,分别造成 20-50% 和 >50% IRAK4 蛋白降解。
- GC62583IRAK-4 protein kinase inhibitor 2CAS: 301675-24-1纯度: >99.00%
IRAK-4 protein kinase inhibitor 2 is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM.
- GC63263ZabedosertibCAS: 1931994-81-8纯度: >99.00%
Zabedosertib (BAY 1834845) is a IRAK4 inhibitor with immunomodulatory potential, which is a protein kinase involved in signaling innate immune responses from Toll-like receptors.
- GC63925JH-X-119-01CAS: 2227368-54-7纯度: >98.00%
JH-X-119-01 is a highly potent and selective covalent inhibitor of IRAK1 with IC50 of 9 nM.
- GC65941HS-276CAS: 2767422-72-8纯度: >98.00%
HS-276, a potent and highly selective orally bioavailable transforming growth factor-β activated kinase-1 (TAK1) inhibitor with the Ki and IC50 of 2.5 nM and 2.3 nM respectively, shows significant inhibition of TNF-mediated cytokine profiles, correlating with significant attenuation of arthritic-like symptoms in the collagen-induced arthritis (CIA) mouse model of inflammatory rheumatoid arthritis (RA).
- GC67879EdecesertibCAS: 2408839-73-4
Edecesertib (GS-5718) 是一种具有选择性且口服有效的 IRAK-4 抑制剂。Edecessertib 具有抗炎活性。Edecessertib 可用于类风湿性关节炎 (RA) 和红斑狼疮 (LE) 的研究。
- GC69288IRAK4-IN-21CAS: 2170694-04-7纯度: >99.00%
IRAK4-IN-21 (化合物 17) 是一种口服有效的和具有选择性的强效 IRAK4 抑制剂,其对 IRAK4 和 TAK1 的 IC50 值分别为 5 和 56 nM。IRAK4-IN-21 能够有效抑制 IL-23 的产生 (IC50=0.17 µM),可用于自身免疫性疾病,如斑块状银屑病和银屑病关节炎的研究。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC11103 | IRAK inhibitor 3 | 1012343-93-9 | >98.00% | |
IRAK inhibitor 3 是一种从专利 WO2008030579 A2 中提取的白细胞介素-1 (IL-I) 受体相关激酶 (IRAK) 激酶调节剂。 | ||||
| GC12651 | IRAK inhibitor 2 | 928333-30-6 | >98.50% | |
IRAK inhibitor 2 是 IL-1 受体相关激酶抑制剂。 | ||||
| GC15999 | IRAK-1-4 Inhibitor I | 509093-47-4 | >99.50% | |
A benzimidazole | ||||
| GC16264 | IRAK inhibitor 4 | 1012104-68-5 | - | |
IRAK inhibitor 4 是一种白细胞介素-1 受体相关激酶 4 (IRAK4) 抑制剂。 | ||||
| GC17158 | IRAK inhibitor 1 | 1042224-63-4 | >99.00% | |
An IRAK4 inhibitor | ||||
| GC17371 | IRAK inhibitor 6 | 1042672-97-8 | >99.50% | |
An IRAK4 inhibitor | ||||
| GC19287 | PF06650833 | 1817626-54-2 | >99.50% | |
PF06650833 (PF-06650833) 是一种有效的、选择性的和口服活性的白细胞介素 1 受体相关激酶 4 (IRAK4) 抑制剂,在细胞和 PBMC 试验中的 IC50 分别为 0.2 和 2.4 nM。 | ||||
| GC20007 | Ginsenoside CK | 39262-14-1 | >98.00% | |
Ginsenoside CK,一种由主要人参皂苷化合物转化而来的次级人参皂苷,比其母体人参皂苷具有更高的生物利用度和溶解性,具有极其重要的意义。 | ||||
| GC31688 | IRAK4-IN-1 | 1820787-94-7 | >99.00% | |
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with IC50 of 7 nM. | ||||
| GC32748 | CA-4948 | 1801343-74-7 | >99.50% | |
An IRAK-4 inhibitor | ||||
| GC33054 | AZ1495 | 2196204-23-4 | >99.50% | |
AZ1495是一种新型的、具有口服活性的白细胞介素-1受体相关激酶4(IRAK4)抑制剂。 | ||||
| GC36328 | IRAK inhibitor 4 trans | - | >99.00% | |
IRAK inhibitor 4 (trans)是IRAK inhibitor 4的trans形式,IRAK inhibitor 4是IRAK4的有效抑制剂。 | ||||
| GC38799 | IRAK4-IN-4 | 1850276-58-2 | >99.50% | |
IRAK4-IN-4 (compound 15) is an inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) and cyclic GMP-AMP synthase (cGAS) with IC50 of 2.8 nM and 2.1 nM, respectively. | ||||
| GC46013 | AS-2444697 (hydrochloride) | 1287665-60-4 | >95.00% | |
An IRAK4 inhibitor | ||||
| GC61944 | IRAK4-IN-6 | 2454244-02-9 | >99.50% | |
IRAK4-IN-6 是一种口服高效、选择性 IRAK 抑制剂,IC50 为 4 nM,靶向 MyD88 L265P 突变型弥漫性大 B 细胞淋巴瘤。 | ||||
| GC62197 | PROTAC IRAK4 degrader-1 | 2360533-90-8 | >99.50% | |
PROTAC IRAK4 degrader-1 是一种 PROTAC IRAK4 降解剂,详细信息请参考专利文献 US20190192668A1 中的化合物 I-210。PROTAC IRAK4 degrader-1 浓度为 0.01,0.1 和 1 μM 时作用于 OCI-LY-10 细胞,分别造成 20-50% 和 >50% IRAK4 蛋白降解。 | ||||
| GC62429 | HS271 | 2410393-15-4 | >99.50% | |
HS271 是一个强效的、口服有效的、选择性的 IRAK4 抑制剂,其 IC50 值为 7.2 μM。HS271 具有优越的体外酶活性和细胞活性,同时也表现出极好的药代动力学特征。 | ||||
| GC62583 | IRAK-4 protein kinase inhibitor 2 | 301675-24-1 | >99.00% | |
IRAK-4 protein kinase inhibitor 2 is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM. | ||||
| GC63263 | Zabedosertib | 1931994-81-8 | >99.00% | |
Zabedosertib (BAY 1834845) is a IRAK4 inhibitor with immunomodulatory potential, which is a protein kinase involved in signaling innate immune responses from Toll-like receptors. | ||||
| GC63925 | JH-X-119-01 | 2227368-54-7 | >98.00% | |
JH-X-119-01 is a highly potent and selective covalent inhibitor of IRAK1 with IC50 of 9 nM. | ||||
| GC65941 | HS-276 | 2767422-72-8 | >98.00% | |
HS-276, a potent and highly selective orally bioavailable transforming growth factor-β activated kinase-1 (TAK1) inhibitor with the Ki and IC50 of 2.5 nM and 2.3 nM respectively, shows significant inhibition of TNF-mediated cytokine profiles, correlating with significant attenuation of arthritic-like symptoms in the collagen-induced arthritis (CIA) mouse model of inflammatory rheumatoid arthritis (RA). | ||||
| GC67879 | Edecesertib | 2408839-73-4 | - | |
Edecesertib (GS-5718) 是一种具有选择性且口服有效的 IRAK-4 抑制剂。Edecessertib 具有抗炎活性。Edecessertib 可用于类风湿性关节炎 (RA) 和红斑狼疮 (LE) 的研究。 | ||||
| GC68458 | HS-243 | 848249-10-5 | - | |
HS-243 是一种有效且选择性的 IRAK-4 和 IRAK-1 抑制剂,IC50 为 20 和 24 nM。HS-243 对 TAK1 (转化生长因子 β 活化激酶 1) 有微弱的抑制活性,IC50 为 0.5 μM。HS-243 具有抗炎和抗癌活性。 | ||||
| GC69288 | IRAK4-IN-21 | 2170694-04-7 | >99.00% | |
IRAK4-IN-21 (化合物 17) 是一种口服有效的和具有选择性的强效 IRAK4 抑制剂,其对 IRAK4 和 TAK1 的 IC50 值分别为 5 和 56 nM。IRAK4-IN-21 能够有效抑制 IL-23 的产生 (IC50=0.17 µM),可用于自身免疫性疾病,如斑块状银屑病和银屑病关节炎的研究。 | ||||
